Given that MDA‐MB‐231 was the only cell line with mutant p53 status among the models used in the literature to test MDM2‐recruiting PROTACs, we aimed to expand the application of MDM2‐based degraders to include an in vitro pancreatic cancer model with mutant p53 status and to strengthen the evidence behind racemic Nutlin‐3 as an accessible ligand for the generation of PROTAC molecules. The gene discussed is MDM2; the disease is pancreatic neoplasm.